Published on : Dec 26, 2017
Albany, New York, December 26, 2017: With modern treatments, it's often possible to control chronic myeloid leukaemia (CML) for many years. Some of the factors such as a rise in research and development in oncology sector, innovation in drug development, new products in the pipeline, and the establishment of novel therapies are resulting in the growth of the global chronic myelogenous leukemia market. A new study, titled “Chronic Myelogenous Leukemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2026” has been publicized to the wide repository of Market Research Hub (MRH), which clearly states that the global market for chronic myelogenous leukemia is likely to witness strong growth, registering 6.7% CAGR during 2017-2026.
Chronic myelogenous leukemia is a type of blood cancer that cannot be cured with normal treatments. Consequently, researchers are also focusing on polypharmacology approach to develop the drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’. Increasing prevalence of chronic myelogenous leukemia in developed countries due to genetic factors is also resulting in the development of new treatment and therapies that are more effective. Hence, a new class of drugs known as Tyrosine-Kinase Inhibitors (TKIs) has been developed that is resulting in the more effective treatment of CML. It is being used on a large scale.
The research also states that key players are entering into the mergers and acquisitions, partnerships, for new product launches and to expand geographically. Based on revenue analysis, it has been analyzed that the market is estimated to bring in US$ 8,550.8 million revenue by 2026 end.
Region-wise, the market has been assessed in some of the prime regions, such as North America, Latin America, Europe, Japan, Asia Pacific Excluding Japan (APEJ), and the Middle East and Africa (MEA). Of these, North America is expected to remain prevailing in the global chronic myelogenous leukemia market through 2026. The region is mainly driven by factors such as presence of leading market players and rise in a number of approval of drugs by the U.S. Food and Drug Administration (FDA).
For a comprehensive view of the market, the market has been analyzed and forecasted for each region, drug type, treatment type and distribution channel for the year 2017-2026. On the basis of treatment type, the segment includes disease-specific treatment and symptomatic treatment. On the basis of drug type, the segment includes branded, and generic. On the basis of the distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, and retail pharmacies. Branded drugs are likely to gain maximum traction in the market, in terms of drug type during 2017-2026.
At last, a section containing detailed data about all the significant players operating in the market has also been included in the report, giving readers access to information such as challenges faced by the companies, the growth strategies implemented, the recent developments reported by them, and the financial and business overview of the company. Various leading market players in the global chronic myelogenous leukemia treatment market include Bristol Myers Squibb, Novartis, Pfizer, Teva Pharmaceutical, Hoffman-LaRoche and Schering Plough, and Others.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1417669
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org